Αποτελέσματα Αναζήτησης
3 Σεπ 2024 · Loading dose: 15 mg/kg infused intravenously over 30 to 60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by more than 50% of baseline. Renal Dose Adjustments. Oral: CrCl less than 10 mL/min: A dosing interval of every 8 to 24 hours is recommended.
8 Μαΐ 2023 · Procainamide is given IV or PO with the onset of action in 10 to 30 minutes. The loading dose is of IV procainamide is 10 to 17 mg/kg and administered at a rate of 20 to 50 mg/min. Alternatively, this may be dosed at 100 mg every 5 minutes in adult patients.
For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
Antiarrhythmic infusions for stable wide-QRS tachycardia procainamide IV dose: 20–50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases > 50% or maximum dose 17 mg/kg given. Maintenance infusion: 1–4 mg/min. Avoid if prolonged QT or CHF. First dose: 150 mg over 10 minutes. Repeat as needed if VT recurs.
Procainamide Hydrochloride Injection is useful for arrhythmias which require immediate suppression and for maintenance of arrhythmia control. Intravenous therapy allows most rapid control of serious arrhythmias, including those following myocardial infarction; it should be carried out in circumstances where close observation and monitoring of ...
procainamide might represent an alternative strategy for pre-venting the recurrence of ventricular tachyarrhythmias and ICD discharges. Procainamide is a class 1a antiarrhythmic agent whose primary mechanism is related to its antagonism of cardiac sodium channels delaying phase 0 of the cardiac cycle. Procainamide and its metabolite N-acetyl ...
